Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : F. Hoffmann-La Roche Limited
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Limited
MAJ Il y a 4 ans
A Mechanism of Action study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe active rheumatoid arthritis (RA)
To investigate the effect of TCZ on markers of atherogenic risk in patients with RA. Primary objectives: • To investigate the effect of 12 weeks of treatment with TCZ on small LDL-L1 particle number •...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
F. Hoffmann-La Roche Limited
MAJ Il y a 4 ans
A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line treatment for patients with HER2 negative metastatic breast cancer
To compare Progression Free Survival (PFS) in patients randomised to • bevacizumab 7.5 mg/kg and docetaxel 100 mg/m[2] q3wk versus docetaxel 100 mg/m[2] and bevacizumab placebo q3wk or • bevacizumab ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Limited
MAJ Il y a 4 ans
An open-label study to characterize the safety and response rate of MabThera (Rituximab) plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukemia
The primary objective of this study is to demonstrate that the combination of rituximab and chlorambucil is safe by examining the adverse event profile.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Limited
MAJ Il y a 4 ans
A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moderate to severe rheumatoid arthritis receiving stable doses of concomitant methotrexate but with unsatisfactory clinical response
The primary objective of this study is to evaluate the safety and tolerability of escalating single intravenous doses of ocrelizumab in combination with methotrexate, in patients with moderate to seve...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations